Patents by Inventor Rajeev Gokhale
Rajeev Gokhale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220218868Abstract: The present invention relates to a hydrogel comprising polysaccharide polymer network and collagen, particularly for use in the wound treatment. The present invention also relates to a wound dressing and a cell culture system comprising the hydrogel and their use in the wound treatment.Type: ApplicationFiled: May 7, 2020Publication date: July 14, 2022Inventors: Chi ZHANG, Shiqi HONG, Rajeev GOKHALE, Pui Lai Rachel EE, Jian Yao NG
-
Patent number: 10105365Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: GrantFiled: June 30, 2017Date of Patent: October 23, 2018Assignee: AbbVie Inc.Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable, Susan George
-
Patent number: 9988272Abstract: Disclosed herein is a process for the synthesis of carbon and carbon based nanocomposites comprising Laser-induced Dissociative Stitching (LDS) from liquid halogen containing aromatic compounds at room temperature.Type: GrantFiled: October 12, 2012Date of Patent: June 5, 2018Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Rohan Rajeev Gokhale, Satishchandra Balkrishna Ogale
-
Publication number: 20170368066Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: ApplicationFiled: June 30, 2017Publication date: December 28, 2017Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
-
Patent number: 9744170Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: GrantFiled: March 18, 2016Date of Patent: August 29, 2017Assignee: AbbVie Inc.Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
-
Publication number: 20160199374Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: ApplicationFiled: March 18, 2016Publication date: July 14, 2016Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
-
Patent number: 9333204Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: GrantFiled: April 2, 2015Date of Patent: May 10, 2016Assignee: AbbVie Inc.Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter A. Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
-
Publication number: 20150258093Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.Type: ApplicationFiled: April 2, 2015Publication date: September 17, 2015Inventors: Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter A. Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
-
Publication number: 20140238842Abstract: Disclosed herein is a process for the synthesis of carbon and carbon based nanocomposites comprising Laser-induced Dissociative Stitching (LDS) from liquid halogen containing aromatic compounds at room temperature.Type: ApplicationFiled: October 12, 2012Publication date: August 28, 2014Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Rohan Rajeev Gokhale, Satishchandra Balkrishna Ogale
-
Patent number: 8557995Abstract: A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.Type: GrantFiled: June 7, 2011Date of Patent: October 15, 2013Assignee: AbbVie Inc.Inventors: Jonathan M. Miller, Rajeev Gokhale, Eric A. Schmitt, Yi Gao, Justin Lafountaine, Lloyd Dias
-
Publication number: 20110312973Abstract: The present invention features solid compositions comprising amorphous Compound I. A solid dispersion of the present invention also contains a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.Type: ApplicationFiled: March 8, 2011Publication date: December 22, 2011Inventors: Bernd Liepold, Karin Rosenblatt, Peter Hoelig, Rajeev Gokhale, Leena Prasad, Jonathan Miller, Eric A. Schmitt, John B. Morris
-
Publication number: 20110306632Abstract: A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.Type: ApplicationFiled: June 7, 2011Publication date: December 15, 2011Applicant: ABBOTT LABORATORIESInventors: Jonathan M. Miller, Rajeev Gokhale, Eric A. Schmitt, Yi Gao, Justin Lafountaine, Lloyd Dias
-
Publication number: 20100323020Abstract: A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D90 particle size not greater than about 3 ?m; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.Type: ApplicationFiled: June 17, 2010Publication date: December 23, 2010Applicant: ABBOTT LABORATORIESInventors: Rajeev Gokhale, Kennan C. Marsh, Yi Shi
-
Publication number: 20100297194Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 25, 2010Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Rajeev Gokhale, Anthony R. Haight, Katherine Heemstra, David Hill, Martin Knobloch, Drazen Kostelac, Justin S. Lafountaine, Yanxia Li, Bernd Liepold, Kennan Marsh, Jonathan M. Miller, Claudia Packhaeuser, Yeshwant D. Sanzgiri, Eric A. Schmitt, Yi Shi, Norbert Steiger, Ping Tong, Huailiang Wu, Geoff G.Z. Zhang, Deliang Zhou
-
Publication number: 20100278921Abstract: An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Cristina M. Fischer, Rajeev Gokhale, Katherine Heemstra, David Hill, Kennan Marsh, Eric A. Schmitt, Yi Shi, Ping Tong, Deliang Zhou
-
Patent number: 7226932Abstract: Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.Type: GrantFiled: April 29, 2003Date of Patent: June 5, 2007Assignee: G.D. Searle LLCInventors: Rajeev Gokhale, Martin J. Griffin, James E. Truelove, James C. Stolzenbach, Aziz Karim, Ajit K. Roy
-
Publication number: 20050013856Abstract: A pharmaceutical composition is provided comprising a drug and a carrier medium, wherein the carrier medium comprisese (a) a matrix forming agent selected from the group consisting of hydroxyethylcelluloses, hydroxypropylcelluloses, hydroxypropylmethylcelluloses, hydroxypropylmethylcellulose phthalates, polyvinylpyrrolidones, polyethylene glycols, polyglycolized glycerides, cyclodextrins, carbomers and combinations thereof, and (b) a filler; and wherein the drug is hygroscopic and/or deliquescent and is dispersed in the carrier medium, and wherein the composition is a solid dispersion and is acceptably non-hygroscopic.Type: ApplicationFiled: December 18, 2003Publication date: January 20, 2005Inventors: Jay Trivedi, Rajeev Gokhale
-
Publication number: 20040048934Abstract: Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.Type: ApplicationFiled: April 29, 2003Publication date: March 11, 2004Applicant: G.D. Searle & Co.Inventors: Rajeev Gokhale, Martin J. Griffin, James E. Truelove, James C. Stolzenbach, Aziz Karim, Ajit K. Roy
-
Publication number: 20030161867Abstract: A dermally deliverable pharmaceutical composition comprises at least one selective cyclooxygenase-2 (COX-2) inhibitory drug or prodrug thereof solubilized in a pharmaceutically acceptable carrier that comprises a low molecular weight monohydric alcohol, and exhibits a skin permeation rate of the therapeutic agent at least equal to that exhibited by a reference solution of the therapeutic agent in 70% aqueous ethanol. A method of effecting targeted delivery of a selective COX-2 inhibitory drug to a site of pain and/or inflammation in a subject comprises topically administering such a composition to skin of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation. A method of effecting systemic treatment of a subject having a COX-2 mediated disorder comprises transdermally administering such a composition, preferably by contacting the composition with an area of skin of the subject not greater than about 400 cm2.Type: ApplicationFiled: May 30, 2002Publication date: August 28, 2003Inventors: Guang Wei Lu, Gary D. Ewing, Praveen Tyle, Brenda M. Stoller, Rajeev Gokhale, Ashwini Gadre